Ventyx Biosciences Inc (VTYX) Actualités

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with...

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory...

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a...

Form 8-K - Current report

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities